Connect Biopharma Holdings logo

CNTB - Connect Biopharma Holdings News Story

$24.57 -1.4  -5.5%

Last Trade - 2:45pm

Mid Cap
Market Cap £1.06bn
Enterprise Value £1.29bn
Revenue £n/a
Position in Universe 2543rd / 6998

Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects

Tue 25th May, 2021 1:00pm
For best results when printing this announcement, please click on link below:

Development program exploring the potential of CBP-174 in the treatment of
chronic inflammatory pruritus

SAN DIEGO and TAICANG, SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Connect
Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the
“Company”), a global clinical-stage biopharmaceutical company dedicated to
improving the lives of patients with chronic inflammatory diseases through the
development of therapies derived from T cell-driven research, today announced
that the first subject has been dosed in a Phase I trial evaluating CBP-174 in
healthy adult subjects.

This randomized, double-blind, placebo-controlled, single ascending dose trial
in healthy subjects, aims to evaluate the safety, tolerability and
pharmacokinetics of CBP-174 in different dose levels given orally, compared to
placebo. Following the single dose, each subject will be followed for up to
seven days (NCT04811469).

“The effective management of pruritus associated with atopic dermatitis and
other inflammatory skin conditions remains a significant unmet medical need,
and the advancement of this novel oral agent into Phase I trial is an
important step forward in the development of potential therapies,” said
Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma. “We believe that
CBP-174’s novel mechanism of action and rapid onset of action has the
potential to complement the anti-pruritic effect of disease-modifying agents
already approved for inflammatory skin diseases.”

About Chronic Inflammatory Pruritus

Chronic inflammatory pruritus is an unpleasant and often persistent itch that
can last more than six weeks in duration and is often caused by inflamed skin
lesions associated with diseases such as atopic dermatitis (AD). Due to the
significant impact that pruritus has on quality of life, its severity is often
measured by patients based on intensity of pruritus rather than skin lesions
themselves. Common antihistamine drugs primarily target the histamine 1
receptor (H1R) and lead to alleviation of itch in part by blocking H1R on
peripheral nerves. However, many types of chronic itch cannot be relieved by
current antihistamine treatments that target H1R. Despite currently available
treatments for AD, an estimated 40% to 50% of AD patients have inadequate
relief of their pruritus and are in need of new, efficacious pruritus

About CBP-174

CBP-174 is a highly potent, orally active, peripherally restricted antagonist
of histamine receptor 3 (H3R), designed not to penetrate the blood brain
barrier. In preclinical studies, CBP-174 was both well-tolerated and
demonstrated significant reductions in scratching bouts within the first 30
minutes of oral or topical dosing, which could potentially translate to rapid
relief of itch in the clinic.

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a global clinical-stage
biopharmaceutical company dedicated to improving the lives of patients living
with chronic inflammatory diseases through the development of therapies
derived from our T cell-driven research.

Our lead product candidate, CBP-201, is an antibody designed to target
interleukin-4 receptor alpha (IL-4Rα) and is currently being evaluated in
clinical trials for the treatment of atopic dermatitis (AD) and asthma and in
development for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second
lead product candidate is CBP-307, a modulator of a T cell receptor known as
sphingosine 1-phosphate receptor 1 (S1P1) that is in development for the
treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore,
we are developing CBP-174, a peripherally restricted antagonist of histamine
receptor 3, for the treatment of pruritus associated with skin inflammation.

With headquarters in China, additional operations in the United States and
Australia, and clinical development activities in those geographies as well as
Europe, Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting several
aspects of T cell biology. For additional information about Connect Biopharma,
please visit our website at


Connect Biopharma cautions that statements included in this press release that
are not a description of historical facts are forward-looking statements.
Words such as "may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," "potential," "continue" or "project" or the negative of these
terms or other comparable terminology are intended to identify forward-looking
statements. These statements include the Company's statements regarding the
potential of CBP-174 to address the unmet needs of patients with chronic
inflammatory pruritus. The inclusion of forward-looking statements should not
be regarded as a representation by Connect Biopharma that any of its plans
will be achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect Biopharma
business and other risks described in the Company's filings with the
Securities and Exchange Commission ("SEC"). Investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof, and Connect Biopharma undertakes no obligation to revise
or update this news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is included in
Connect Biopharma's filings with the SEC which are available from the SEC's
website ( and on Connect Biopharma's website
( under the heading "Investors." All forward-looking
statements are qualified in their entirety by this cautionary statement. This
caution is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.

IR/PR Contacts:
Lazar FINN Partners 
David Carey (IR) 
T: +1-(212) 867-1768

Erich Sandoval (Media)
T: +1-(917)-497-2867

Corporate Contacts:


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.